Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

150%(3 trials)

Terminated

1(33%)

Phase Distribution

Ph not_applicable

33%

Ph phase_3

33%

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (33.3%)

Phase 41 (33.3%)

N/A1 (33.3%)

Trials by Status

terminated133%

completed267%

Recent Activity

0 active trials

Showing 3 of 3

completednot_applicable

Oxcarbazepine Versus Placebo in Childhood Autism

NCT00467753

completedphase_3

A Randomized, Placebo-controlled, Tourette Syndrome Study.

NCT00206323

terminatedphase_4

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

NCT01349114

Clinical Trials (3)

Showing 3 of 3 trials

NCT00467753Not Applicable

Oxcarbazepine Versus Placebo in Childhood Autism

Completed

NCT00206323Phase 3

A Randomized, Placebo-controlled, Tourette Syndrome Study.

Completed

NCT01349114Phase 4

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3